Key Points
- United Therapeutics CEO Martine Rothblatt sold 9,500 shares on May 18 at an average price of $567.04, totaling about $5.39 million. After the sale, Rothblatt held 40,513 shares, a 19% reduction in her position.
- UTHR shares were trading near their recent highs, opening at $566.80, with a 52-week range of $272.12 to $609.35 and a market cap of about $24.06 billion. The stock’s 50-day and 200-day moving averages were $561.48 and $509.54, respectively.
- The company recently missed quarterly expectations, reporting EPS of $5.82 versus the $7.00 consensus and revenue of $781.5 million versus $797.4 million expected. Despite that, analysts remain constructive, with a consensus rating of “Moderate Buy” and an average target price of $619.42.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, May 18th. The stock was sold at an average price of $567.04, for a total transaction of $5,386,880.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,972,491.52. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
United Therapeutics Price Performance
Shares of UTHR opened at $566.80 on Wednesday. The company has a market capitalization of $24.06 billion, a PE ratio of 20.92, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company's fifty day moving average price is $561.48 and its 200 day moving average price is $509.54.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business's revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $6.63 EPS. Analysts anticipate that United Therapeutics Corporation will post 27.07 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the company. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price target on the stock. Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. HC Wainwright boosted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a report on Tuesday, March 31st. Finally, Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an "outperform" rating on the stock in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $619.42.
Read Our Latest Report on UTHR
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of UTHR. Torren Management LLC acquired a new position in shares of United Therapeutics in the fourth quarter valued at $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics in the fourth quarter valued at $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
